Portal de Periódicos da CAPES

Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals

1993; Elsevier BV; Volume: 30; Issue: 10 Linguagem: Inglês

10.1016/0161-5890(93)90019-8

1872-9142

Harold Deulofeut, Antonio Iglesias, Hagy Mikael, David H. Bing, Zuheir L. Awdeh, Juan J. Yunis, Deborah Marcus-Bagley, Margot S. Kruskall, Chester A. Alper, Edmond J. Yunis,

Immunotherapy and Immune Responses

Vaccination with native HBsAg results in both a humoral and a cellular immune response in humans. In individuals who responded to vaccination, the HBsAg (S region) specific response, as measured by cell proliferation, diminished significantly after 12 weeks, a time when the antibody response was still vigorous. Reduced and nonreduced HBsAg were equivalent in eliciting lymphocyte proliferation. Anti-MHC class II monoclonal antibodies were used in blocking studies to demonstrate that anti-HLA-DR but not anti-HLA-DQ or anti-HLA-DP inhibited specific lymphocyte proliferation to HBsAg. Both the monomer (reduced) and dimer (nonreduced) forms of an immunodominant midsequence HBsAg peptide (amino acid residues 139–146) produced lymphocyte proliferation roughly comparable to that induced by whole HBsAg in 6 of 7 responders immunized with whole HBsAg and the peptide-induced proliferation was blocked by anti-HLA-DR but not by anti-HLA-DP antibodies. These results suggest that HBsAg p 139–146 is a major immunodominant peptide of HBsAg and is restricted by HLA-DR.